Role of cetuximab and XXXX in treatment of metastatic @entity14 .

@entity1 @entity470 @entity984 @entity5 @entity2857 @entity10412 @entity14 @entity817
BACKGROUND: The relationship of @entity470 ( @entity470 ) pathway, such as @entity10412 , @entity984 , and @entity817 , with response to @entity470 -targeted antibodies is less well studied. AIM: To assess @entity2857 with cetuximab in treating metastatic @entity14 . SETTINGS AND DESIGN: Thirty-five @entity1 with metastatic @entity14 were randomized to receive cetuximab with or without oral @entity2857 . @entity1 AND METHODS: @entity1 received cetuximab i.v. weekly for four weeks and oral @entity2857 twice daily on days 1-28, with recycling every four weeks. The primary end point was the response rate (partial and complete), while the secondary end points were the adverse effects, time to progression and overall survival. STATISTICAL ANALYSIS: was made using the Statistical Product and Service Solutions, using SPSS 10.0, with estimation of both time to progression and overall survival time by the Kaplan-Meier method and comparing the two groups with the use of a log-rank test. RESULTS: Partial response was higher in cetuximab- @entity2857 (EN), which constituted 33.3% compared to 17.6% in the cetuximab group (P = 0.44). Progression-free survival had a statistically higher significant difference in wild @entity984 compared to mutant @entity984 cases (P = .0001). Median overall survival was seven and five months in the (EN) and (E) groups respectively (P = 0.49). CONCLUSION: @entity984 and @entity817 was a predictor of response, so genotyping of @entity5 was needed for defining the @entity1 population that was likely to benefit from the targeted therapy. A combination of therapy that simultaneously targets @entity984 and @entity817 could be a useful approach to increase the number of @entity1 who may benefit from anti- @entity470 therapy.
